You have read all your free articles, to continue reading subscribe to read the rest of this content.
AstraZeneca provides an update on its Immuno-Oncology (IO) late-stage clinical development programme in 1st-line non-small cell lung cancer (NSCLC), including a refinement of the Phase III MYSTIC trial. The MYSTIC trial was initially designed to assess the benefit of durvalumab monotherapy and duAlready a subscriber Login You have read all…
Positive results from the PROpel Phase III trial showed AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) versus current standard-of-care abiratAlready a subscriber Login You have read all your free articles, to continue reading subscribe to read the…
The company has completed a planned 12 week interim analysis in the its Phase 2 proof-of-concept study of its bispecific molecule ABY-035 for moderate-to-severe psoriasis (“AFFIRM 35”). “Our Phase 2 AFFIRM-35 study with ABY-035 has now reached the stage where we are starting to see the firsAlready a subscriber Login…
Collective data from recently completed toxicity studies show that the product candidate SN132D can be given safely at doses that widely exceeds the expected clinical dose. At the end of 2016, Spago Nanomedical formally announced its product candidate in the SpagoPix project. The product candidatAlready a subscriber Login You have…
